Lucentis

France wants Avastin used in place of Lucentis

Meanwhile, France and the EU have both been making noises about pursuing their own investigations into the companies' Lucentis dealings. ... Lucentis has been a big earner for both companies, featuring at number 19 in PMLiVE's Top 50 pharmaceutical

Allergan will start phase III DARPin trials next year

s big-selling Lucentis (ranibizumab), while having a longer duration of action that means it should require fewer injections into the eye. ... Chief executive David Pyott pointed out that Bayer's Eylea (aflibercept) has made dramatic gains in market

Novartis and NHS launch mobile eye unit in UK

Novartis' interests in the area lie in Lucentis (ranibizumab), which is recommended by the National Institute for Health and Care Excellence (NICE) to treat wet AMD among other eye conditions. ... Bayer's drug is recommended as a monthly treatment for

Bayer files eye drug Eylea for new use in EU

Registration would also help Bayer in its tussle for market share in the macular disease area with Novartis' Lucentis (ranibizumab), which is already approved for BRVO but only in patients who

Novartis licenses Ophthotech eye drug in $1bn deal

Novartis already sells anti-VEGF (vascular endothelial growth factor) drug Lucentis (ranibizumab) for wet AMD - as well as other indications such as pathological myopia and macular oedema - and achieved sales of ... Competition in the AMD sector is on

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]